U.S. markets closed
  • S&P Futures

    4,164.00
    -12.25 (-0.29%)
     
  • Dow Futures

    33,980.00
    -101.00 (-0.30%)
     
  • Nasdaq Futures

    13,988.00
    -41.50 (-0.30%)
     
  • Russell 2000 Futures

    2,250.70
    -8.30 (-0.37%)
     
  • Crude Oil

    62.81
    -0.32 (-0.51%)
     
  • Gold

    1,777.30
    -2.90 (-0.16%)
     
  • Silver

    25.99
    -0.12 (-0.46%)
     
  • EUR/USD

    1.1972
    -0.0009 (-0.07%)
     
  • 10-Yr Bond

    1.5730
    +0.0430 (+2.81%)
     
  • Vix

    16.25
    -0.32 (-1.93%)
     
  • GBP/USD

    1.3822
    -0.0018 (-0.13%)
     
  • USD/JPY

    108.7000
    -0.0830 (-0.08%)
     
  • BTC-USD

    55,990.83
    -5,306.95 (-8.66%)
     
  • CMC Crypto 200

    1,263.85
    -127.86 (-9.19%)
     
  • FTSE 100

    7,019.53
    +36.03 (+0.52%)
     
  • Nikkei 225

    29,683.37
    +40.67 (+0.14%)
     

Sanofi posts positive results for drug in chronic sinusitis

PARIS, Sept 30 (Reuters) - Sanofi and its U.S. partner Regeneron on Tuesday unveiled positive mid-stage trial results for their experimental drug dupilumab in patients with chronic sinusitis with nasal polyps.

In a Phase IIa trial, the injectable drug met all primary and secondary endpoints in affected patients who did not respond to intranasal corticosteroids, Sanofi said in a statement.

Dupilumab is also being tested by the drugmakers against two other allergic conditions - atopic dermatitis and asthma.

(Reporting by Natalie Huet; Editing by Blaise Robinson)